The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 3, 1999, Pages 553-561

  Vicini, Frank A ^a   Kestin, Larry L ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Biochemical failure; Prostate; Prostate specific antigen; Prostatic neoplasms; Radiotherapy

Indexed keywords

ALKALINE PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE;

EID: 0032880126     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00235-7     Document Type: Article

References (38)

1. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 36:1996;565-571.
2. Kaplan I.D., Cox R.S., Bagshaw M.A. Prostate specific antigen after external beam radiotherapy for prostate cancer Follow-up . J Urol. 149:1993;519-522.
3. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. Prostate specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;307-316.
4. Ritter M.A., Messing E.M., Shanahan T.G., et al. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol. 10:1992;1208-1217.
5. Russell K.J., Dunatov C., Hafermann M.D., et al. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol. 146:1991;1046-1052.
6. Zagars G.K., von Eschenbach A.C. Prostate-specific antigen An important marker for prostate cancer treated by external beam radiation therapy . Cancer. 72:1993;538-548.
7. Zagars G.K., Pollack A., Kavadi V.S., et al. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;293-306.
8. Crook J.M., Bahadur Y.A., Bociek R.G., et al. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systemic biopsy and serum prostate specific antigen. Cancer. 79:1997;328-336.
9. Hanks G.E., D'Amico A., Epstein B.E., et al. Prostate specific antigen doubling times in patients with prostate cancer A potentially useful reflection of tumor doubling time . Int J Radiat Oncol Biol Phys. 27:1993;125-127.
10. Zeitman A.L., Shipley W.U. Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer. 71:1993;959-969.
11. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer Do we know how to use it? Semin Radiat Oncol. 8:1998;72-80.
12. Schellhammer P.F., El-Mahdi A.M., Kuban D.A., et al. Prostate-specific antigen after radiation therapy. Urol Clin North Am. 24:1997;407-414.
13. Aref I., Eapen L., Agboola O., et al. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma. Radiother Oncol. 48:1998;203-207.
14. Critz F.A., Levinson A.K., Williams W.H., et al. Prostate-specific antigen nadir The optimum level after irradiation for prostate cancer . J Clin Oncol. 14:1996;2893-2900.
15. Critz F.A., Levinson A.K., Williams W.H., et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology. 49:1997;322-326.
16. Crook J.M., Choan E., Perry G.A., et al. Serum prostate-specific antigen profile following radiotherapy for prostate cancer Implications for patterns of failure and definition of cure . Urology. 51:1998;566-572.
17. Goad J.R., Chang S., Ohori M., et al. PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am. 20:1993;727-736.
18. Hanlon A.L., Moore D.F., Hanks G.E. Modeling postradiation prostate specific antigen level kinetics. Cancer. 83:1998;130-134.
19. Lee W.R., Hanlon A.L., Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer The relationship between nadir level and disease free survival . J Urol. 156:1996;450-453.
20. Sartor C.I., Strawderman M.H., Lin X., et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 38:1997;941-947.
21. Zietman A.L., Tibbs M.K., Dallow K.C., et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 40:1996;159-162.
22. D'Amico A.V., Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 72:1993;2638-2643.
23. Hancock S.L., Cox R.S., Bagshaw M.A. Prostate-specific antigen after radiotherapy for prostate cancer A reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University . J Urol. 154:1995;1412-1417.
24. Stamey T.A., Ferrari M.K., Schmid H.P. The value of serial prostate specific antigen determinations 5 years after radiotherapy Steeply increasing values characterize 80% of patients [letter] . J Urol. 152:1994;492-495.
25. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 44:1997;213-221.
26. Chodak G.W., Neumann J., Blix G., et al. Effect of external beam radiation therapy on serum prostate-specific antigen. Urology. 35:1990;288-294.
27. Zagars G.K., Pollack A. The fall and rise of prostate-specific antigen. Cancer. 72:1993;832-842.
28. Ennis R.D., Malyszko B.K., Heitjan D.F., et al. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 41:1998;511-517.
29. D'Amico A.V., Whittington R., Malkowicz S.B., et al. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;473-477.
30. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
31. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys. 41:1998;267-272.
32. Prostate. Fleming I.D., Cooper J.S., Henson D.E., et al. AJCC cancer staging manual. 5th ed. 1998;203-207 Lippincott-Raven, Philadelphia.
33. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
34. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
35. Cox D.R. Regression models and life-tables. J R Stat Soc B. 34:1972;187-220.
36. Willet C.G., Zietman A.L., Shipley W.U., et al. The effect of pelvic radiation therapy on the production of prostatic specific antigen. J Urol. 151:1994;1579-1581.
37. Zeitman A.L., Zehr E.M., Shipley W.U. Long-term effect of PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. Int J Radiat Oncol Biol Phys. 43:1999;715-718.
38. McLaughlin P.W., Sandler H.M., Jiroutek M.R. Prostate-specific antigen following prostate radiotherapy How low can you go? [letter] J Clin Oncol. 14:1996;2889-2892.